UroToday - The Global Online Community of Urologists
– First Patient Dosed in Expanded Access Program and Enrollment Ongoing – Reno, Nevada (UroToday.com) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical …
UroToday - The Global Online Community of Urologists
UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.
About UroToday
About UroToday-GU Oncology Today ® UroToday - GU Oncology Today brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology …
UroToday
UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.
UroToday Video Channels
UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.
Journal Club Videos - UroToday
UroToday's exclusive Video Lecture coverage of Journal Club. Combination Therapy Associated with Significantly Higher Rates of MFS Compared with ADT Alone Among Men with High-Risk …
ASCO GU 2024 Prostate Cancer - UroToday
ASCO GU 2024: The NEPI Trial: A Randomized Phase I/II Study of Neoadjuvant Treatment with 177-Lutetium-PSMA-617 with or without Ipilimumab in Patients with Very High-Risk Prostate …
The Latest Research on Bladder Cancer - UroToday
Bladder cancer remains the sixth most commonly diagnosed cancer in the United States, with an estimated 82,290 incident cases in 2023. 1 Because of the persistent recurrence risk of …
Prostate Cancer - UroToday
Sep 25, 2024 · Prostate Cancer-related Events in Patients with Synchronous Metastatic Hormone-sensitive Prostate Cancer Treated with Androgen Deprivation Therapy with and …
ASCO 2022 - UroToday
ASCO 2022 Bladder Cancer. ASCO 2022: Preliminary Results of a Phase Ib/II Combination Study of RC48-ADC, a Novel Humanized Anti-HER2 Antibody-Drug Conjugate With Toripalimab, a …